查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1586205

中枢神经系统药物市场：依药物类别、疾病、药物类型、通路划分 - 2025-2030 年全球预测

Central Nervous System Drugs Market by Drug Classes (Analgesics, Anesthetics, Anti-Epileptics), Diseases (CNS Trauma, Infectious Diseases, Mental Health), Drug Type, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

中枢神经系统药物市场2023年估值为207.1亿美元，预计2024年将达224.4亿美元，复合年增长率为9.85%，预计到2030年将达到399.9亿美元。

中枢神经系统（CNS）药物涵盖了旨在治疗影响大脑和脊髓疾病的药物的重要领域。此领域涵盖广泛的药物，包括神经退化性疾病、精神疾病、疼痛管理等的治疗。神经和精神疾病的日益流行、有效治疗慢性疼痛的需要以及神经技术的进步推动了对中枢神经系统治疗的需求。它具有广泛的应用范围，包括阿兹海默症、帕金森氏症、忧郁症、焦虑症、多发性硬化症和癫痫症，解决未满足的医疗需求，并提高患者的生活品质。最终用途范围从医院、诊所到家庭护理，其中受中枢神经系统疾病影响的老年人、儿童和成人人口大量使用。影响该市场的关键成长要素包括人口老化、心理健康意识的提高、医疗保健支出的增加以及精准医疗和生物标记识别等技术创新。最近的潜在商机在于生技药品和基因疗法的开发，以及利用人工智慧进行药物发现和个人化医疗。公司可以透过投资策略伙伴关係关係和研发来利用这些优势。然而，高昂的研发成本、严格的法律规范以及神经学研究的复杂性为市场成长带来了挑战。神经保护疗法、生物相似药和增强药物传输系统等领域的创新和研究可能会蓬勃发展，特别是在神经肿瘤学和罕见的中枢神经系统疾病领域。中枢神经系统疾病药物市场多样化且快速发展，要求公司在监管环境、竞争环境和数位健康技术整合方面保持领先地位。为了应对这一复杂的情况并实现成长，公司必须优先考虑以患者为中心的方法，投资于尖端研究，并开展合作研究，以加强其治疗管道并探索进入新兴市场的机会。

主要市场统计
基准年[2023] 207.1亿美元
预测年份 [2024] 224.4亿美元
预测年份 [2030] 399.9亿美元
复合年增长率（%） 9.85%

市场动态：快速发展的中枢神经系统药物市场的关键市场洞察

供需的动态交互作用正在改变中枢神经系统药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球神经病变和认知障碍的发生率不断增加
    • 增加政府计划和宣传活动，以传播有关神经系统危险因素和症状的知识
    • 患有神经系统併发症的老年人口不断增加
  • 市场限制因素
    • 药物发现和开发需要昂贵的资本投资和充足的基础设施。
  • 市场机会
    • 持续的药物研发以满足精神病学和神经科特定的不断变化的需求
    • 在中枢神经系统药物发现中采用人工智慧和机器学习
  • 市场挑战
    • 严格的产品核可规定和对产品召回的担忧
    • 儘管有足够的研究，但缺乏神经病学领域的专业知识

波特五力：驾驭中枢神经系统药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对中枢神经系统药物市场的影响

外部宏观环境因素在塑造中枢神经系统药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解中枢神经系统药物市场的竞争状况

中枢神经系统药物市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV 定位矩阵中枢神经系统药物市场供应商的绩效评估

FPNV 定位矩阵是评估中枢神经系统药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了中枢神经系统药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，中枢神经系统药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球神经和认知障碍的发生率不断增加
      • 增加政府计划和宣传活动，以传播有关神经系统危险因素和症状的知识
      • 患有神经系统併发症的老年人口不断增加
    • 抑制因素
      • 药物发现和开发需要大量资本投资和适当的基础设施
    • 机会
      • 持续药物开发以满足精神病学和神经病学领域独特且不断变化的需求
      • 中枢神经系统药物发现中引入人工智慧和机器学习
    • 任务
      • 严格的产品核可规定和对产品召回的担忧
      • 儘管有足够的研究，但缺乏神经病学领域的主题专业知识
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依药物类别分類的中枢神经系统药物市场

  • 止痛药
  • 麻醉剂
  • 抗癫痫药
  • 抗帕金森氏症药物
  • 抗忧郁症

第七章依疾病分类的中枢神经系统药物市场

  • 中枢神经系统创伤
  • 感染疾病
  • 心理健康
  • 神经退化性疾病
  • 神经血管疾病

第八章中枢神经系统药物市场（依药物类型）

  • 生物製药
  • 非生技药品

第九章中枢神经系统药物市场：依分销管道分类

  • 医院药房
  • 在线的
  • 零售药房

第十章美洲中枢神经系统药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太中枢神经系统药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲中枢神经系统药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Astex 和卡迪夫大学宣布合作发现新药
    • Newlux Farm 宣布完成对赛诺菲现有产品的收购
    • Precision Life 与工业建立中枢神经系统疾病多标靶伙伴关係
    • 合作将重点放在中枢神经系统疾病的治疗目标
    • Intrinsic Medicine 与 Phoenix Biotech 签署合併协议
    • Solid Biosciences 宣布在收购 AavantiBio 的同时进行 7,500 万美元私募
    • Gencyc开始开发合作
    • IAMA Therapeutics 与义大利理工学院合作，进行神经科学药物发现的突破性研究。
    • 艾伯维 (AbbVie) 和 Gedeon Richter 宣布在神经精神疾病领域开展合作
    • 艾伯维 (AbbVie) 收购 Syndesi Therapeutics 以加强神经科学产品组合
  • 战略分析和建议

公司名单

  • AN Pharmacia Laboratories Pvt. Ltd.
  • AbbVie Inc.
  • Alkermes PLC
  • Apotex Inc.
  • Arvelle Therapeutics International GmbH by Angelini Pharma Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma
  • BIAL-PORTELA & CA, SA
  • Biogen Inc.
  • Catalent, Inc.
  • CNS Pharmaceuticals, Inc.
  • Daiichi Sankyo Company, Limited
  • Divi's Laboratories Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • East India Pharmaceutical Works Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Endo International PLC by DuPont de Nemours, Inc.
  • Eridanus Healthcare
  • EVERSANA
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Intas Pharmaceuticals Ltd.
  • Jabs Biotech Pvt. Ltd.
  • Johnson & Johnson Services, Inc.
  • La Renon Healthcare Pvt. Ltd.
  • Lupin Ltd.
  • Merck & Co.
  • Micro Labs Ltd.
  • Midas Pharma GmbH
  • Neuracle Lifesciences Private Limited
  • Neurocon Inc.
  • Novartis Group
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Priavoid GmbH
  • Reliance Formulations Pvt. Ltd.
  • Sanofi SA
  • Servier Laboratories（Aust）Pty Ltd
  • Shine Pharmaceuticals Ltd.
  • Somacare
  • SteriMax Inc.
  • Sun Pharmaceuticals Pvt Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • UCB SA
  • Wellona Pharma
  • Zee Laboratories Limited
Product Code: MRR-434CCDA05199

The Central Nervous System Drugs Market was valued at USD 20.71 billion in 2023, expected to reach USD 22.44 billion in 2024, and is projected to grow at a CAGR of 9.85%, to USD 39.99 billion by 2030.

Central Nervous System (CNS) Drugs encompass a critical domain within pharmaceuticals aimed at treating disorders affecting the brain and spinal cord. This segment covers a broad range of medications, including treatments for neurodegenerative diseases, mental health disorders, and pain management. The necessity for CNS drugs is driven by the growing prevalence of neurological and psychiatric conditions, the need for effective management of chronic pain, and advancements in neurotechnology. Applications range across Alzheimer's, Parkinson's, depression, anxiety, multiple sclerosis, and epilepsy, addressing unmet medical needs and enhancing patient quality of life. The end-use scope extends to hospitals, clinics, and home care settings, with significant uptake from geriatric, pediatric, and adult populations impacted by CNS disorders. Key growth factors influencing this market include an aging demographic, increased mental health awareness, rising healthcare expenditures, and technological innovations such as precision medicine and biomarker identification. Recent potential opportunities lie in developing biologics, gene therapies, and leveraging artificial intelligence for drug discovery and personalized medicine. Companies can capitalize on these by investing in strategic partnerships and R&D. However, market growth is challenged by high R&D costs, stringent regulatory frameworks, and the complexity of neurological research, which result in longer timelines and uncertain outcomes. Innovation and research can thrive in areas like neuroprotective therapies, biosimilars, and enhancing drug delivery systems, particularly within neuro-oncology and rare CNS disorders. The CNS drugs market is diverse and rapidly evolving, requiring businesses to stay ahead of regulatory landscapes, competitive dynamics, and the integration of digital health technologies. To navigate these complexities and capitalize on growth, firms must prioritize patient-centric approaches, invest in cutting-edge research, and explore collaborations that enhance therapeutic pipelines and access to emerging markets.

KEY MARKET STATISTICS
Base Year [2023] USD 20.71 billion
Estimated Year [2024] USD 22.44 billion
Forecast Year [2030] USD 39.99 billion
CAGR (%) 9.85%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Central Nervous System Drugs Market

The Central Nervous System Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing incidence of neurological and cognitive disorders across the globe
    • Ascending government programs and awareness activities to spread the knowledge about neurological risk factors and symptoms
    • Rise in geriatric population with neurological complications
  • Market Restraints
    • Requirement of high capital investment and adequate infrastructure for drug discovery and development
  • Market Opportunities
    • Ongoing drug evolvement to meet the unique and changing demands of psychiatry and neurology field
    • Adoption of artificial intelligence and machine learning in CNS drug discovery
  • Market Challenges
    • Stringent regulations for product approvals and concern regarding product recalls
    • Dearth of subject expertise in the neurological field amid the competent studies

Porter's Five Forces: A Strategic Tool for Navigating the Central Nervous System Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Central Nervous System Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Central Nervous System Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Central Nervous System Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Central Nervous System Drugs Market

A detailed market share analysis in the Central Nervous System Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Central Nervous System Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Central Nervous System Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Central Nervous System Drugs Market

A strategic analysis of the Central Nervous System Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Central Nervous System Drugs Market, highlighting leading vendors and their innovative profiles. These include A. N. Pharmacia Laboratories Pvt. Ltd., AbbVie Inc., Alkermes PLC, Apotex Inc., Arvelle Therapeutics International GmbH by Angelini Pharma Inc., AstraZeneca PLC, Aurobindo Pharma, BIAL - PORTELA & CA, S.A., Biogen Inc., Catalent, Inc., CNS Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Divi's Laboratories Ltd., Dr. Reddy's Laboratories Ltd., East India Pharmaceutical Works Ltd., Eisai Co., Ltd., Eli Lilly and Company, Endo International PLC by DuPont de Nemours, Inc., Eridanus Healthcare, EVERSANA, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, H. Lundbeck A/S, Intas Pharmaceuticals Ltd., Jabs Biotech Pvt. Ltd., Johnson & Johnson Services, Inc., La Renon Healthcare Pvt. Ltd., Lupin Ltd., Merck & Co., Micro Labs Ltd., Midas Pharma GmbH, Neuracle Lifesciences Private Limited, Neurocon Inc., Novartis Group, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Priavoid GmbH, Reliance Formulations Pvt. Ltd., Sanofi S.A., Servier Laboratories (Aust) Pty Ltd, Shine Pharmaceuticals Ltd., Somacare, SteriMax Inc., Sun Pharmaceuticals Pvt Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., UCB S.A., Wellona Pharma, and Zee Laboratories Limited.

Market Segmentation & Coverage

This research report categorizes the Central Nervous System Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Classes, market is studied across Analgesics, Anesthetics, Anti-Epileptics, Anti-Parkinson Drugs, and Antidepressant.
  • Based on Diseases, market is studied across CNS Trauma, Infectious Diseases, Mental Health, Neurodegenerative Diseases, and Neurovascular Diseases.
  • Based on Drug Type, market is studied across Biologics and Non-Biologics.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidence of neurological and cognitive disorders across the globe
      • 5.1.1.2. Ascending government programs and awareness activities to spread the knowledge about neurological risk factors and symptoms
      • 5.1.1.3. Rise in geriatric population with neurological complications
    • 5.1.2. Restraints
      • 5.1.2.1. Requirement of high capital investment and adequate infrastructure for drug discovery and development
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing drug evolvement to meet the unique and changing demands of psychiatry and neurology field
      • 5.1.3.2. Adoption of artificial intelligence and machine learning in CNS drug discovery
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations for product approvals and concern regarding product recalls
      • 5.1.4.2. Dearth of subject expertise in the neurological field amid the competent studies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Central Nervous System Drugs Market, by Drug Classes

  • 6.1. Introduction
  • 6.2. Analgesics
  • 6.3. Anesthetics
  • 6.4. Anti-Epileptics
  • 6.5. Anti-Parkinson Drugs
  • 6.6. Antidepressant

7. Central Nervous System Drugs Market, by Diseases

  • 7.1. Introduction
  • 7.2. CNS Trauma
  • 7.3. Infectious Diseases
  • 7.4. Mental Health
  • 7.5. Neurodegenerative Diseases
  • 7.6. Neurovascular Diseases

8. Central Nervous System Drugs Market, by Drug Type

  • 8.1. Introduction
  • 8.2. Biologics
  • 8.3. Non-Biologics

9. Central Nervous System Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online
  • 9.4. Retail Pharmacies

10. Americas Central Nervous System Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Central Nervous System Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Central Nervous System Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Astex and Cardiff University announce drug discovery collaboration
    • 13.3.2. Neuraxpharm announces closing of acquisition of established products from Sanofi
    • 13.3.3. PrecisionLife and Ono sign multi-target partnership for CNS disorders
    • 13.3.4. Collaboration will focus on therapy targets for CNS disorders
    • 13.3.5. Intrinsic Medicine enters merger deal with Phoenix Biotech
    • 13.3.6. Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement
    • 13.3.7. Gensaic enters into collaboration to develop
    • 13.3.8. IAMA Therapeutics Partners with the Italian Institute of Technology to Embark on Landmark Research on Neuroscience Drug Discovery
    • 13.3.9. AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases
    • 13.3.10. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. A. N. Pharmacia Laboratories Pvt. Ltd.
  • 2. AbbVie Inc.
  • 3. Alkermes PLC
  • 4. Apotex Inc.
  • 5. Arvelle Therapeutics International GmbH by Angelini Pharma Inc.
  • 6. AstraZeneca PLC
  • 7. Aurobindo Pharma
  • 8. BIAL - PORTELA & CA, S.A.
  • 9. Biogen Inc.
  • 10. Catalent, Inc.
  • 11. CNS Pharmaceuticals, Inc.
  • 12. Daiichi Sankyo Company, Limited
  • 13. Divi's Laboratories Ltd.
  • 14. Dr. Reddy's Laboratories Ltd.
  • 15. East India Pharmaceutical Works Ltd.
  • 16. Eisai Co., Ltd.
  • 17. Eli Lilly and Company
  • 18. Endo International PLC by DuPont de Nemours, Inc.
  • 19. Eridanus Healthcare
  • 20. EVERSANA
  • 21. F. Hoffmann-La Roche AG
  • 22. GlaxoSmithKline PLC
  • 23. H. Lundbeck A/S
  • 24. Intas Pharmaceuticals Ltd.
  • 25. Jabs Biotech Pvt. Ltd.
  • 26. Johnson & Johnson Services, Inc.
  • 27. La Renon Healthcare Pvt. Ltd.
  • 28. Lupin Ltd.
  • 29. Merck & Co.
  • 30. Micro Labs Ltd.
  • 31. Midas Pharma GmbH
  • 32. Neuracle Lifesciences Private Limited
  • 33. Neurocon Inc.
  • 34. Novartis Group
  • 35. Otsuka Pharmaceutical Co., Ltd.
  • 36. Pfizer Inc.
  • 37. Priavoid GmbH
  • 38. Reliance Formulations Pvt. Ltd.
  • 39. Sanofi S.A.
  • 40. Servier Laboratories (Aust) Pty Ltd
  • 41. Shine Pharmaceuticals Ltd.
  • 42. Somacare
  • 43. SteriMax Inc.
  • 44. Sun Pharmaceuticals Pvt Ltd.
  • 45. Takeda Pharmaceutical Co. Ltd.
  • 46. Teva Pharmaceutical Industries Ltd.
  • 47. Torrent Pharmaceuticals Ltd.
  • 48. UCB S.A.
  • 49. Wellona Pharma
  • 50. Zee Laboratories Limited

LIST OF FIGURES

  • FIGURE 1. CENTRAL NERVOUS SYSTEM DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CENTRAL NERVOUS SYSTEM DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CENTRAL NERVOUS SYSTEM DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CENTRAL NERVOUS SYSTEM DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CENTRAL NERVOUS SYSTEM DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANESTHETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTI-PARKINSON DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIDEPRESSANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS TRAUMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MENTAL HEALTH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NEUROVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. CENTRAL NERVOUS SYSTEM DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. CENTRAL NERVOUS SYSTEM DRUGS MARKET, FPNV POSITIONING MATRIX, 2023